99725-12-9

Usage

Uses

Used in Pharmaceutical Industry:
2-Fluoro-5-bromobenzyl bromide is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to modify the molecular structure of drugs, potentially enhancing their efficacy and selectivity.
Used in Agrochemical Industry:
In the agrochemical sector, 2-Fluoro-5-bromobenzyl bromide is utilized as a precursor in the development of new agrochemicals, contributing to the creation of more effective and targeted pesticides and other agricultural products.
Used in Organic Synthesis:
2-Fluoro-5-bromobenzyl bromide is employed as a versatile building block in organic synthesis, allowing for the construction of complex organic molecules with tailored properties for various applications in research and industry.

InChI:InChI=1/C7H5Br2F/c8-4-5-3-6(9)1-2-7(5)10/h1-3H,4H2

Upstream product

• 51437-00-4 5-bromo-2-fluorotoluene 
• 99725-13-0 (5-bromo-2-fluorophenyl)methanol 
• 93777-26-5 5-bromo-2-fluorobenzaldehyde 
• 2094-98-6 1,1'-azobis (cyclohexanecarbonitrile) 
• 603-35-0 triphenylphosphine 

Downstream Products

• 99748-26-2 2-(acetoxymethyl)-4-bromo-1-fluorobenzene 
• 205055-67-0 3-(S)-(tert-butoxycarbonylamino)-1-(5-bromo-2-fluorobenzyl)pyrrolidin-2-one 
• 728033-28-1 4-(5-bromo-2-fluorophenyl)-butyric acid 
• 728033-48-5 1-(5-benzyloxy-8-formylnaphthalen-1-yloxy)-5-methoxymethoxynaphthalene-4-carbaldehyde 
• 205055-68-1 3-(S)-(tert-butoxycarbonylamino)-1-(5-cyano-2-fluorobenzyl)pyrrolidin-2-one 
• 205055-70-5 5-pyridin-3-ylthiophene-2-sulfonic acid [1-(5-cyano-2-fluorobenzyl)-2-oxopyrrolidin-3-(S)-yl]amide 
• 99725-13-0 (5-bromo-2-fluorophenyl)methanol 
• 99725-14-1 4-bromo-1-fluoro-2-<<<(1,1-dimethylethyl)dimethylsilyl>oxy>methyl>benzene 
• 305800-60-6 2-(5-bromo-2-fluorophenyl)acetonitrile 
• 258886-07-6 4-(5-bromo-2-fluorobenzyl)-5-methoxy-2,4-dihydro-3H-1,2,4-triazol-3-one 
• 93777-26-5 5-bromo-2-fluorobenzaldehyde 
• 942154-51-0 1-(5.bromo-2-fluorobenzyl)-1H-1,2,4-triazole 
• 1262859-92-6 4-bromo-1-fluoro-2-nitromethyl-benzene 

Relevant academic research and scientific papers

ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS

The present invention relates to a compound represented by formula I: and pharmaceutically acceptable salts thereof. The compounds of formula I are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS

The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof. The compounds of formula I are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF

The present application relates to novel carboxylic acid derivatives having an oxo-substituted azaheterocyclic partial structure, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for producing medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prevention of cardiovascular disorders.

1,2,4-TRIAZOL-l-YL BISPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF ENDOCRINE-DEPENDENT TUMOURS

There is provided a compound of Formula I wherein R3, R4, R5, R6 and R7 are independently selected from H and -Y-R6; wherein each R8 is independently selected from -OH, hydrocarbyl groups, oxyhydrocarbyl groups, cyano (-CN), nitro (-NO2), H-bond acceptors, and halogens; wherein at Jeast one of R3, R4, R5, R6 and R7 is -Y-R8 wherein R8 is selected from substituted and unsubstituted ? heterocyclic rings and amino substituted phenyl groups, wherein X is a bond or a linker group; wherein Y is an optional linker group; and wherein ring A is optionally further , substituted; wherein R9 is selected from H, -OH and -OSO2NR1R2; wherein R1 and R2 are independently selected from H and hydrocarbyl; wherein (a) X is a bond and at least one of R3, R4, R5, R6 and R7 is -Y-R8; OR (b) R9 is -OSO2NR1R2 or - OH and four of R3, R4, R5, R6 and R7 are H and one of R3, R4, R5, R6 and R7 is -Y-R8. These compounds inhibit steroid sulphatase and aronatase activity and are useful in the treatment of endocrine-dependent tumours.

1-BENZYLINDOLE-2-CARBOXAMIDE DERIVATIVES

The present invention relates to i-benzylindole-2-carboxamide derivatives of formula I, or a pharmaceutically acceptable salt or solvate thereof. The invention also relates to pharmaceutical compositions comprising said 1-benzylindole-2-carboxamide deriva

Triazolone derivatives, use thereof, and intermediates therefor

Triazolone derivatives represented by the formula wherein R1represents optionally substituted C1-10alkyl, A1—L1—, A1—ON═CA2, etc.; R2represents hydrogen, C1-6alkyl, etc.; R3represents C1-6alkoxy, etc.; one of T, U, and V represents CR4, another represents CH or nitrogen, and the remaining one represents CR5or nitrogen; and W represents CR6or nitrogen.

Cyclocarbamate derivatives as progesterone receptor modulators

This invention provides compounds of Formula (I): wherein R1 and R2 may be single substituents or fused to form spirocyclic or hetero-spirocyclic rings; R3 is H, OH, NH2, C1 to C6 alkyl, substituted C1 to C6 alkyl, C3 to C6 alkenyl, substituted C1 to C6 alkenyl, alkynyl, or substituted alkynyl, CORC; RC is H, C1 to C3 alkyl, substituted C1 to C3 alkyl, aryl, substituted aryl, C1 to C3 alkoxy, substituted C1 to C3 alkoxy, C1 to C3 aminoalkyl, or substituted C1 to C3 aminoalkyl; R4 is H, halogen, CN, NO2, C1 to C6 alkyl, substituted C1 to C6 alkyl, alkynyl, or substituted alkynyl, C1 to C6 alkoxy, substituted C1 to C6 alkoxy, amino, C1 to C6 aminoalkyl, or substituted C1 to C6 aminoalkyl; and R5 is selected from a trisubstituted benzene ring of a five or six membered ring with 1, 2, or 3 heteroatoms from the group including O, S, SO, SO2 or NR6 and containing one or two independent substituents from the group including H, halogen, CN, NO2, amino, and C1 to C3 alky, C1 to C3 alkoxy, C1 to C3 aminoalkyl, CORF, or NRGCORF; or pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions and methods using the compounds as antagonists of the progesterone receptor.

Combination regimens using progesterone receptor modulators

This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure: wherein R1and R2may be single substituents or fused to form spirocyclic or hetero-spirocyclic rings; R3is H, OH, NH2, C1to C6alkyl, substituted C1to C6allyl C3to C6alkenyl, substituted C1to C6alkenyl, alkynyl, or substituted alknyl, CORC; RCis H, C1to C3alkyl, substituted C1to C3alkyl, aryl, substituted aryl, C1to C3alkoxy, substituted C1to C3alkoxy, C1to C3aminoalkyl, or substituted C1to C3aminoalkyl; R4is H, halogen, CN, NO2, C1to C6alkyl, substituted C1to C6alkyl alkynyl, or substituted alkynyl, C1to C6alkoxy, substituted C1to C6alkoxy, amino, C1to C6aminoalkyl, or substituted C1to C6aminoalkyl; and R5is selected from a trisubstituted benzene ring of a five or six membered ring with 1, 2, or 3 heteroatoms from the group including O, S, SO, SO2or NR6and containing one or two independent substituents from the group including H, halogen, CN, NO2, amino, and C1to C3alkyl, C1to C3alkoxy, C1to C3aminoalkyl, CORF, or NRGCORF; or pharmaceutically acceptable salt thereof. These methods of treatment may be used for contraception or for the treatment and/or prevention of secondary amenorrhea, dysfunctional bleeding, uterine leiomyomata, endometriosis; polycystic ovary syndrome, carcinomas and adenocarcinomas of the endometrium, ovary, breast, colon, prostate, or inmization of side effects or cyclic menstrual bleeding. Additional uses of the invention include stimulation of food intake.

Substituted sulfonic acid N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds

The compounds of formula I exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, which are for treating a patient suffering from, or subject to, physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.

Sulfonamidopyrrolidinone factor Xa inhibitors: Potency and selectivity enhancements via P-1 and P-4 optimization

Sulfonamidopyrrolidinones were previously disclosed as a selective class of factor Xa (fXa) inhibitors, culminating in the identification of RPR120844 as a potent member with efficacy in vivo. Recognizing the usefulness of the central pyrrolidinone template for the presentation of ligands to the S-1 and S-4 subsites of fXa, studies to optimize the P-1 and P-4 groups were initiated. Sulfonamidopyrrolidinones containing 4-hydroxy- and 4- aminobenzamidines were discovered to be effective inhibitors of fXa. X-ray crystallographic experiments in trypsin and molecular modeling studies suggest that our inhibitors bind by insertion of the 4-hydroxybenzamidine moiety into the S-1 subsite of the fXa active site. Of the P-4 groups examined, the pyridylthienyl sulfonamides were found to confer excellent potency and selectivity especially in combination with 4-hydroxybenzamidine. Compound 20b (RPR130737) was shown to be a potent fXa inhibitor (K1 = 2 nM) with selectivity against structurally related serine proteinases (> 1000 times). Preliminary biological evaluation demonstrates the effectiveness of this inhibitor in common assays of thrombosis in vitro (e.g. activated partial thromboplastin time) and in vivo (e.g. rat FeCl2-induced carotid artery thrombosis model).